Themis Bioscience Chikungunya vaccine in clinical trials

Viennese biotech company Themis Bioscience announced the start of a phase I clinical study on its Chikungunya fever vaccine. The vaccine candidate, which is based on a standard anti-measles vaccine, will be evaluated More...